[Claims]

[Claim 1]

A pharmaceutical composition containing luliconazole or a pharmaceutically acceptable salt thereof as an active ingredient, the pharmaceutical composition comprising:

7 to 12% by mass of the luliconazole or the pharmaceutically acceptable salt thereof relative to a total mass of the pharmaceutical composition;

a polyethylene glycol having an average molecular weight of 380 to 420 represented by a formula $HOCH_2(CH_2OCH_2)_nCH_2OH$ where n is an integer;

ethanol;

benzyl alcohol;

lactic acid;

propylene carbonate; and

3 to 10 % by mass of acetone relative to a total mass of the pharmaceutical composition.

[Claim 2]

The pharmaceutical composition according to claim 1, wherein the luliconazole or the pharmaceutically acceptable salt thereof is contained at 7 to 10% by mass relative to the total mass of the pharmaceutical composition.

[Claim 3]

The pharmaceutical composition according to claim 1 or 2, wherein the polyethylene glycol having an average molecular weight of 380 to 420 represented by the formula $HOCH_2(CH_2OCH_2)_nCH_2OH$ where n is an integer is contained at 5 to 40% by mass relative to the total mass of the pharmaceutical composition.

[Claim 4]

The pharmaceutical composition according to any one of claims 1 to 3, wherein the ethanol is contained at 20 to 70% by mass relative to the total mass of the pharmaceutical composition.

[Claim 5]

The pharmaceutical composition according to claim 4, wherein the ethanol is contained at 30% by mass or more and less than 50% by mass relative to the total mass

of the pharmaceutical composition.

[Claim 6]

The pharmaceutical composition according to any one of claims 1 to 5, wherein the benzyl alcohol is contained at 0.01 to 10% by mass relative to the total mass of the pharmaceutical composition.

[Claim 7]

The pharmaceutical composition according to any one of claims 1 to 6, wherein the lactic acid is contained at 1 to 10% by mass relative to the total mass of the pharmaceutical composition.

[Claim 8]

The pharmaceutical composition according to any one of claims 1 to 7, wherein the propylene carbonate is contained at 1 to 15% by mass relative to the total mass of the pharmaceutical composition.

[Claim 9]

The pharmaceutical composition according to any one of claims 1 to 8, further comprising isopropyl myristate.

[Claim 10]

The pharmaceutical composition according to claim 9, wherein the isopropyl myristate is contained at 1 to 10% by mass relative to the total mass of the pharmaceutical composition.

[Claim 11]

The pharmaceutical composition according to any one of claims 1 to 10, further comprising a film forming agent.

[Claim 12]

The pharmaceutical composition according to claim 11, wherein the film forming agent contains a mixture of an acrylic resin alkanolamine and ethanol, or a mixture of (alkyl acrylate/diacetone acrylamide) copolymer AMP and ethanol.

[Claim 13]

The pharmaceutical composition according to claim 11 or 12, wherein the film forming agent is contained at 0.01 to 4% by mass relative to the total mass of the pharmaceutical composition.

[Claim 14]

The pharmaceutical composition according to any one of claims 1 to 13, further comprising N-methyl-2-pyrrolidone.

[Claim 15]

The pharmaceutical composition according to any one of claims 1 to 13, which is free of N-methyl-2-pyrrolidone.

[Claim 16]

Use of the pharmaceutical composition according to any one of claims 1 to 15, in the manufacture of a medicament for the treatment or prevention of onychomycosis.

[Claim 17]

The use according to claim 16, wherein the onychomycosis is distal subungual onychomycosis.

[Claim 18]

The use according to claim 16 or 17, wherein the onychomycosis is an infection of toenails.

[Claim 19]

The use according to claim 16 or 17, wherein the onychomycosis is an infection of fingernails .

[Claim 20]

The use according to any one of claims 16 to19, wherein the pharmaceutical composition is an external medicine

[Claim 21]

The use according to claim 20, wherein the pharmaceutical composition is applied to an affected area once a day

[Claim 22]

A method of preparing the pharmaceutical composition according to any one of claims 1 to 15, the method comprising mixing the luliconazole or the pharmaceutically acceptable salt thereof with the polyethylene glycol having an average molecular weight of 380 to 420 represented by the formula $HOCH_2(CH_2OCH_2)_nCH_2OH$ where n is an integer, the ethanol, the benzyl alcohol, the lactic acid, the propylene carbonate, and the acetone.

[Claim 23]

The pharmaceutical composition according to any one of claims 1 to 15 for use in the treatment or prevention of onychomycosis.